{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T15:32:23Z","timestamp":1696519943358},"reference-count":27,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2011,9,28]],"date-time":"2011-09-28T00:00:00Z","timestamp":1317168000000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutical Statistics"],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:p>The increasing concern of antibacterial resistance has been well documented, as has the relative lack of antibiotic development. This paradox is in part due to challenges with clinical development of antibiotics. Because of their rapid progression, untreated bacterial infections are associated with significant morbidity and mortality. As a consequence, placebo\u2010controlled studies of new agents are unethical. Rather, pivotal development studies are mostly conducted using non\u2010inferiority designs versus an active comparator. Further, infections because of comparator\u2010resistant isolates must usually be excluded from the trial programme. Unfortunately, the placebo\u2010controlled data classically used in support of non\u2010inferiority designs are largely unavailable for antibiotics. The only available data are from the 1930s and 1940s and their use is associated with significant concerns regarding constancy and assay sensitivity. Extended public debate on this challenge has led to proposed solutions by some in which these concerns are addressed by using very conservative approaches to trial design, endpoints and non\u2010inferiority margins, in some cases leading to potentially impractical studies. To compound this challenge, different Regulatory Authorities seem to be taking different approaches to these key issues. If harmonisation does not occur, antibiotic development will become increasingly challenging, with the risk of further decreases in the amount of antibiotic drug development. However with clarity on Regulatory requirements and an ability to feasibly conduct global development programmes, it should be possible to bring much needed additional antibiotics to patients. Copyright \u00a9 2011 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/pst.518","type":"journal-article","created":{"date-parts":[[2011,9,28]],"date-time":"2011-09-28T13:32:55Z","timestamp":1317216775000},"page":"454-460","source":"Crossref","is-referenced-by-count":6,"title":["Active controlled studies in antibiotic drug\u2009development"],"prefix":"10.1002","volume":"10","author":[{"given":"Aaron","family":"Dane","sequence":"first","affiliation":[{"name":"AstraZeneca  Macclesfield Cheshire UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,9,28]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-6-200009190-00014"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1425"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1198\/sbr.2010.09016"},{"key":"e_1_2_6_5_1","unstructured":"CHMP guideline on the choice of the non inferiority margin January2006.http:\/\/www.ema.europa.eu\/docs\/en\\_GB\/document\\_library\/Scientific\\_guideline\/2009\/09\/WC500003636.pdf."},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.10.1152"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1081\/BIP-120037178"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2855"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3073"},{"key":"e_1_2_6_10_1","unstructured":"International Conference on Harmonization. Guidance on choice of control group and related design and conduct issues in clinical trials (ICH E\u201010) International Conference on Harmonization July2000."},{"issue":"5","key":"e_1_2_6_11_1","first-page":"S397","article-title":"Combating antimicrobial resistance: policy recommendations to save lives","volume":"52","author":"IDSA","year":"2011","journal-title":"Clinical Infectious Diseases"},{"key":"e_1_2_6_12_1","unstructured":"Guidance for industry non\u2010inferiority clinical trials. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) DRAFT March2010.http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM202140.pdf."},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1086\/524891"},{"key":"e_1_2_6_14_1","unstructured":"Guidance for industry.Antibacterial drug products: use of noninferiority trials to support approval. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) FINAL November2010.http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM070951.pdf."},{"key":"e_1_2_6_15_1","unstructured":"Guidance for industry.Community acquired bacterial pneumonia: developing drugs for treatment. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) DRAFT 2009.http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM123686.pdf."},{"key":"e_1_2_6_16_1","unstructured":"Guidance for industry.Acute bacterial skin and skin structure infections: developing drugs for treatment. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) DRAFT August2010.http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM071185.pdf."},{"key":"e_1_2_6_17_1","unstructured":"Guidance for industry.Hospital\u2010acquired bacterial pneumonia and ventilator\u2010associated bacterial pneumonia: developing drugs for treatment. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) DRAFT 2010; pp.20\u201327http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM234907.pdf."},{"issue":"7","key":"e_1_2_6_18_1","first-page":"S469\u2013S476","article-title":"New rules for clinical trials of patients with acute bacterial skin and skin\u2010structure infections: do not let the perfect be the enemy of the good","volume":"52","author":"Corey RC","year":"2011","journal-title":"Clinical Infectious Diseases"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1198\/sbr.2010.09016COMM1"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1198\/sbr.2010.09016COMM2"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.218"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1400"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1086\/591390"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1086\/591411"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1086\/600296"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/009286151004400208"},{"key":"e_1_2_6_27_1","unstructured":"Summary Minutes of the Anti\u2010Infective Drugs Advisory Committee November 18\u201020 2008. (Skin)http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/08\/minutes\/2008\u20104394m1\u2010final\\%2018\\%20nov.pdf."},{"key":"e_1_2_6_28_1","unstructured":"Summary Minutes of the Anti\u2010Infective Drugs Advisory Committee on April 1& 2 2008. (CAP)http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/08\/minutes\/2008\u20104343m1\u2010FINAL.pdf."}],"container-title":["Pharmaceutical Statistics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpst.518","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pst.518","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T12:45:01Z","timestamp":1694609101000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pst.518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1002\/pst.518"],"URL":"https:\/\/doi.org\/10.1002\/pst.518","archive":["Portico"],"relation":{},"ISSN":["1539-1604","1539-1612"],"issn-type":[{"value":"1539-1604","type":"print"},{"value":"1539-1612","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}